Results 91 to 100 of about 866 (110)

Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections

American Journal of Obstetrics and Gynecology, 2022
Thorsten Degenhardt, Stacey Curelop, Stephen Brand   +2 more
exaly  

Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis

SAGE Open Medicine, 2022
Mark Martens
exaly  

Oteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis

Future Microbiology, 2021
Jack D Sobel, Paul R Nyirjesy
exaly  

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy

Drug Design, Development and Therapy, 2023
exaly  

The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause

Climacteric, 2018
Santiago Palacios, Rossella E Nappi, Nick Panay   +2 more
exaly  

Vulvovaginal candidosis

Lancet, The, 2007
Jack D Sobel
exaly  

Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study

American Journal of Obstetrics and Gynecology, 2004
Jack D Sobel, Paul R Nyirjesy, Betsy Foxman   +2 more
exaly  

A 12-week treatment with fractional CO2laser for vulvovaginal atrophy: a pilot study

Climacteric, 2014
Rossella E Nappi, Nicola Zerbinati, Simone Ferrero   +2 more
exaly  

Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis

American Journal of Obstetrics and Gynecology, 1985
Jack D Sobel
exaly  

Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations

American Journal of Obstetrics and Gynecology, 1998
Jack D Sobel, Betsy Foxman, Paul R Nyirjesy   +2 more
exaly